STAT+: Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval

A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in a late-stage trial.